Study of Toxic and Protective Effects of Drugs on Cardiovascular System












            ******************************************************************************************

            *
            ******************************************************************************************
            Study of Toxic and Protective Effects of Drugs on Cardiovascular System [ URL "http://port

            Centers/UNCE1/?lang=en-GB"]

            Cardiovascular toxicity of drugs is among the important complications of today’s pharmacot

            drugs have off target potential to damage the heart and vessels; however, the most importa
            been associated with anticancer chemotherapy.


            The main objectives of the research are:


            (i) research of molecular mechanisms of cardiovascular toxicity of traditional as well as 
            drugs.


            (ii) study of possibilities to protect the heart using established and newly synthesized d
            including the structure activity and pharmacodynamic/pharmacokinetic relationships, effect
            effectiveness and advanced drug delivery methods.


            (iii) study of vascular protection and development of novel drugs with vascular targeted p
            therapy.


            This research is characterized by multidisciplinary approach – from rational design and sy
            potential drug, through assessment of their therapeutic effects using in vitro and in vivo

            safety/toxicity determinations to analysis their pharmacokinetics. This project aims to br
            complementary skills, knowledge, and resources in new ways, in order to jointly address th
            problems. The research team is composed of 20 researchers students from 7 departments of t

            University Faculties of Pharmacy and Medicine in Hradec Králové.





            ******************************************************************************************

            * Selected outputs
            ******************************************************************************************
            • Jirkovský E, Jirkovská A, Bureš J, Chládek J, Lenčová O, Stariat J, Pokorná Z, Karabanov

              Brázdová P, Šimůnek T, Kovaříková P, Štěrba M. Pharmacokinetics of the Cardioprotective 
              and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. Journal of
              and Experimental Therapeutics. 2018; 364(3):433-446

            • Bures J, Jirkovska A, Sestak V, Jansova H, Karabanovich G, Roh J, Sterba M, Simunek T, K
              Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective ef
              topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. 2017; 392: 1-10

            • Machacek M, Demuth J, Cermak P, Vavreckova M, Hruba L, Jedlickova A, Kubat P, Simunek T,
              V, Zimcik P, Tetra(3,4-pyrido)porphyrazines caught in the cationic cage: toward nanomola
              photosensitizers, Journal of Medicinal Chemistry, 2016, 59(20): 9443–9456.